Abstract
During the eight years between the first and second editions, much has transpired in the field of psychiatry. The<i>Diagnostic and Statistical Manual of Mental Disorders</i>has evolved from the third edition (<i>DSM-III</i>) through a revision in 1987 (<i>DSM-III-R</i>) to the 1994 fourth edition (<i>DSM-IV</i>). The selective serotonin reuptake inhibitors have become first-line antidepressants. Serotonin uptake inhibitors (including clomipramine) have been a boon to those with obsessive-compulsive disorder (a condition described as "rare in the general population" in<i>DSM-III</i>but more recently recognized to have a one-year prevalence of 1.5% to 2.1%). Clozapine has offered hope in otherwise treatmentresistant schizophrenia. Enormous strides have been made in neurobiology, neuropharmacology, and neuroimaging. Specific psychotherapies (behavioral, cognitive, interpersonal) have withstood the rigors of carefully conducted research and are becoming more widely disseminated treatments. The editors are cognizant of these recent advances and planned to incorporate them into the second edition, writing, "It is
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
